Lantern Pharma (NASDAQ:LTRN) Director Acquires $100,000.64 in Stock

Posted by Francis Steltz on May 14th, 2026

Lantern Pharma Inc. (NASDAQ:LTRN – Get Free Report) Director Lee Troy Schalop acquired 48,544 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The shares were bought at an average price of $2.06 per share, for a total transaction of $100,000.64. Following the completion of the acquisition, the director owned 48,544 shares of the company’s stock, valued at $100,000.64. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Lantern Pharma Stock Up 24.7%

LTRN traded up $0.62 during trading on Thursday, hitting $3.13. The company had a trading volume of 1,252,820 shares, compared to its average volume of 440,871. The company has a market capitalization of $35.38 million, a PE ratio of -1.99 and a beta of 2.10. Lantern Pharma Inc. has a one year low of $1.11 and a one year high of $5.74. The firm’s 50-day moving average price is $2.21 and its 200 day moving average price is $2.93.

Lantern Pharma (NASDAQ:LTRN – Get Free Report) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.10.

Analyst Upgrades and Downgrades

LTRN has been the subject of a number of analyst reports. Weiss Ratings raised shares of Lantern Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, May 7th. Wall Street Zen raised shares of Lantern Pharma to a “sell” rating in a research report on Saturday, May 9th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

View Our Latest Stock Analysis on Lantern Pharma

Institutional Investors Weigh In On Lantern Pharma

Hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its holdings in shares of Lantern Pharma by 10.3% during the 4th quarter. Renaissance Technologies LLC now owns 110,400 shares of the company’s stock worth $335,000 after buying an additional 10,300 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Lantern Pharma by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 96,742 shares of the company’s stock worth $293,000 after buying an additional 4,661 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Lantern Pharma by 5.6% during the 3rd quarter. Vanguard Group Inc. now owns 384,041 shares of the company’s stock worth $1,671,000 after buying an additional 20,321 shares during the period. CIBC Private Wealth Group LLC bought a new stake in shares of Lantern Pharma during the 4th quarter worth about $47,000. Finally, Susquehanna International Group LLP bought a new stake in shares of Lantern Pharma during the 3rd quarter worth about $170,000. 28.62% of the stock is currently owned by institutional investors and hedge funds.

Lantern Pharma Company Profile

(Get Free Report)

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.